The effect of omega-3 fatty acids on Barrett's oesophagus

St George's Healthcare NHS Trust0 个研究点目标入组 0 人开始时间: 2007年6月14日最近更新: 2019年11月25日

试验速览

暂无简介。

•Any patient, male or female, aged 18+ undergoing endoscopic surveillance for Barrett's oesophagus.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•. Patients who are allergic to fish (cannot take tablets)
•·Pregnant or breast-feeding patients (although there is no known harm associated with the capsules we are not keen to give them to pregnant people in case of unknown harmful effects)
•. Patients with a bleeding diathesis/disorder
•·Patients who are taking warfarin or other anticoagulants (excluding aspirin) - (EPA can interact with warfarin and increase bleeding risk)
•. Patients with known gastrointestinal malabsorption
•·Patients with known dysplasia at previous endoscopy
•·Patients who are taking other fish-oil supplements (eg cod liver oil) who are unwilling to stop them for the duration of the study
•·Patients deemed mentally incompetent.
•·Patients considered by their physician unlikely to be able to comply with the protocol

发起方

St George's Healthcare NHS Trust